Literature DB >> 2982505

In vivo effects of cyclosporine on influenza A virus-infected mice.

E Schiltknecht, G L Ada.   

Abstract

Cyclosporine (cyclosporin A, CsA) administered to mice substantially affects their immune response to an influenza A virus infection. If treated with CsA for 21 days, the mouse lungs contain high titers of virus which are cleared more slowly than in controls. Indicators of pathological damage--lung weight, extent of consolidation, fine morphology, and the extent of infiltration of dividing cells into the lung--showed that administration of CsA greatly decreased the level of inflammation. The production of hemagglutination-inhibiting (HI) antibody was delayed but reached almost control levels and NK cell activity in the lung was also comparable to control levels. In contrast, a delayed-type hypersensitivity (DTH) response to the virus could not be elicited in the CsA-treated, infected mice at 6 or 12 days after infection. Cytotoxic-T-cell (Tc-cell) activity was present in the lungs of such mice though its appearance was delayed and the activity recovered was less than that of the control infected mice. If administered with a dose of virus lethal for normal mice. CSA-treated mice survived, probably due to the greatly reduced level of immunopathological damage in the infected lung.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2982505     DOI: 10.1016/0008-8749(85)90046-2

Source DB:  PubMed          Journal:  Cell Immunol        ISSN: 0008-8749            Impact factor:   4.868


  13 in total

1.  Augmentation of delayed-type hypersensitivity to high dose sheep erythrocytes by cyclosporin A in the mouse: influence of drug dosage and route of administration and analysis of spleen cell populations.

Authors:  L M Webster; A W Thomson
Journal:  Clin Exp Immunol       Date:  1988-01       Impact factor: 4.330

2.  Effects of cyclosporin A on humoral immune response and resistance against vesicular stomatitis virus in mice.

Authors:  S Charan; A W Huegin; A Cerny; H Hengartner; R M Zinkernagel
Journal:  J Virol       Date:  1986-03       Impact factor: 5.103

3.  Mechanism of recovery from acute virus infection. II. Effect of treatment of mice with cyclosporin A on their ability to eliminate the lymphocytic choriomeningitis virus.

Authors:  C Löliger; F Lehmann-Grube
Journal:  Med Microbiol Immunol       Date:  1985       Impact factor: 3.402

4.  Cyclosporin A inhibits the influenza virus replication through cyclophilin A-dependent and -independent pathways.

Authors:  Xiaoling Liu; Zhendong Zhao; Zheng Li; Chongfeng Xu; Lei Sun; Jilong Chen; Wenjun Liu
Journal:  PLoS One       Date:  2012-05-15       Impact factor: 3.240

5.  Effect of cyclosporin A on an experimental chronic viral infection of the central nervous system.

Authors:  O Boespflug; C Godfraind; M Tardieu
Journal:  J Neuroimmunol       Date:  1989-01       Impact factor: 3.478

Review 6.  Is there a role for cyclophilin inhibitors in the management of primary biliary cirrhosis?

Authors:  Shawn T Wasilenko; Aldo J Montano-Loza; Andrew L Mason
Journal:  Viruses       Date:  2013-01-24       Impact factor: 5.048

7.  Pathogenicity of pandemic H1N1 influenza A virus in immunocompromised cynomolgus macaques.

Authors:  Van Loi Pham; Misako Nakayama; Yasushi Itoh; Hirohito Ishigaki; Mitsutaka Kitano; Masahiko Arikata; Hideaki Ishida; Naoko Kitagawa; Shintaro Shichinohe; Masatoshi Okamatsu; Yoshihiro Sakoda; Hideaki Tsuchiya; Shinichiro Nakamura; Hiroshi Kida; Kazumasa Ogasawara
Journal:  PLoS One       Date:  2013-09-23       Impact factor: 3.240

Review 8.  Multi-Omics Studies towards Novel Modulators of Influenza A Virus-Host Interaction.

Authors:  Sandra Söderholm; Yu Fu; Lana Gaelings; Sergey Belanov; Laxman Yetukuri; Mikhail Berlinkov; Anton V Cheltsov; Simon Anders; Tero Aittokallio; Tuula A Nyman; Sampsa Matikainen; Denis E Kainov
Journal:  Viruses       Date:  2016-09-29       Impact factor: 5.048

Review 9.  Cyclophilins and cyclophilin inhibitors in nidovirus replication.

Authors:  Adriaan H de Wilde; Uyen Pham; Clara C Posthuma; Eric J Snijder
Journal:  Virology       Date:  2018-07-12       Impact factor: 3.616

Review 10.  Cyclosporine and COVID-19: Risk or favorable?

Authors:  Nadia Nicholine Poulsen; Albrecht von Brunn; Mads Hornum; Martin Blomberg Jensen
Journal:  Am J Transplant       Date:  2020-09-07       Impact factor: 9.369

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.